TY - JOUR
T1 - A comprehensive appraisal of dabigatran etexilate clinical evidence and applications
T2 - A 10-year-long story
AU - Romiti, Giulio Francesco
AU - Corica, Bernadette
AU - Proietti, Marco
N1 - Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/3
Y1 - 2021/3
N2 - During the last decade, non-vitamin K antagonist oral anticoagulants (NOACs) revolutionized the thromboprophylaxis management of several medical conditions, including atrial fibrillation and venous thromboembolism. Dabigatran etexilate was the first NOAC widely available worldwide, and it is currently the only one that directly inhibits thrombin. More recently, the availability of idarucizumab, a specific reversal agent, has increased the safety of dabigatran use in clinical practice, especially for those patients with severe and life-threatening bleeding. This review aims to summarize current evidence on dabigatran, starting from its pharmacological characteristics, and providing an updated overview of pivotal randomized controlled trials and real-world data on its efficacy and safety.
AB - During the last decade, non-vitamin K antagonist oral anticoagulants (NOACs) revolutionized the thromboprophylaxis management of several medical conditions, including atrial fibrillation and venous thromboembolism. Dabigatran etexilate was the first NOAC widely available worldwide, and it is currently the only one that directly inhibits thrombin. More recently, the availability of idarucizumab, a specific reversal agent, has increased the safety of dabigatran use in clinical practice, especially for those patients with severe and life-threatening bleeding. This review aims to summarize current evidence on dabigatran, starting from its pharmacological characteristics, and providing an updated overview of pivotal randomized controlled trials and real-world data on its efficacy and safety.
KW - atrial fibrillation
KW - dabigatran
KW - non-vitamin K antagonist oral anticoagulants
KW - oral anticoagulant drugs
KW - thromboembolic risk
UR - http://www.scopus.com/inward/record.url?scp=85101088057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101088057&partnerID=8YFLogxK
U2 - 10.2217/fca-2020-0084
DO - 10.2217/fca-2020-0084
M3 - Article
C2 - 32883107
AN - SCOPUS:85101088057
VL - 17
SP - 215
EP - 226
JO - Future Cardiology
JF - Future Cardiology
SN - 1479-6678
IS - 2
ER -